Top

Open Access 27-03-2024 | Cholangiocarcinoma | ORIGINAL ARTICLE

Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study

Authors: Motoko Sasaki, Yasunori Sato, Yasuni Nakanuma

Abstract

Genetic alterations including fusions in fibroblast growth factor receptor 2 (FGFR2) are detected in 10–20% of intrahepatic cholangiocarcinoma (iCCA), and FGFR2 inhibitors are effective for the treatment of iCCA. We examined a prevalence of FGFR2 genetic alterations and their clinicopathological significance in combined hepatocellular–cholangiocarcinoma (cHCC-CCA). FGFR2 expression, which is a surrogate marker for FGFR2 genetic alterations, was immunohistochemically assessed in the liver sections from 75 patients with cHCC-CCA, 35 with small duct-type iCCA, 30 with large duct-type iCCA, and 35 with hepatocellular carcinoma (HCC). FGFR2 genetic alterations were detected by reverse transcription-PCR and direct sequence. An association of FGFR2 expression with clinicopathological features was investigated in cHCC-CCAs. FGFR2 expression was detected in significantly more patients with cHCC-CCA (21.3%) and small duct-type iCCA (25.7%), compared to those with large duct-type iCCA (3.3%) and HCC (0%) (p < 0.05). FGFR2-positive cHCC-CCAs were significantly smaller size (p < 0.05), with more predominant cholangiolocarcinoma component (p < 0.01) and less nestin expression (p < 0.05). Genetic alterations of ARID1A and BAP1 and multiple genes were significantly more frequent in FGFR2-positive cHCC-CCAs (p < 0.05). 5′/3′ imbalance in FGFR2 genes indicating exon18-truncated FGFR2 was significantly more frequently detected in FGFR2-positive cHCC-CCAs and small duct iCCAs, compared to FGFR2-negative ones (p < 0.05). FGFR2::BICC fusion was detected in a case of cHCC-CCAs. FGFR2 genetic alterations may be prevalent in cHCC-CCAs as well as small duct-type iCCAs, which suggest cHCC-CCAs may also be a possible therapeutic target of FGFR2 inhibitors.

Graphical Abstract

Available only for authorised users

Sempoux C, Kakar S, Kondo F, Schirmacher P (2019) Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma. In: the WHO Classification of Tumours Editorial Board (ed) WHO classification of tumours. Digestive system tumours, 5th edn. International Agency for Research on Cancer (IARC), Lyon, pp 260-262

Beaufrere A, Calderaro J, Paradis V (2021) Combined hepatocellular cholangiocarcinoma: an update. J Hepatol 74:1212–1224. https://doi.org/10.1016/j.jhep.2021.01.035CrossRefPubMed

Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G et al (2018) cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 68:113–126. https://doi.org/10.1002/hep.29789CrossRefPubMed

Nguyen CT, Caruso S, Maille P, Beaufrere A, Augustin J, Favre L et al (2022) Immune profiling of combined hepatocellular- cholangiocarcinoma reveals distinct subtypes and activation of gene signatures predictive of response to immunotherapy. Clin Cancer Res 28:540–551. https://doi.org/10.1158/1078-0432.CCR-21-1219CrossRefPubMed

Murugesan K, Sharaf R, Montesion M, Moore JA, Pao J, Pavlick DC et al (2021) Genomic profiling of combined hepatocellular cholangiocarcinoma reveals genomics similar to either hepatocellular carcinoma or cholangiocarcinoma. JCO Precis Oncol 5 https://doi.org/10.1200/PO.20.00397

Xue R, Chen L, Zhang C, Fujita M, Li R, Yan SM et al (2019) Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell 35(932–947):e938. https://doi.org/10.1016/j.ccell.2019.04.007CrossRef

Joseph NM, Tsokos CG, Umetsu SE, Shain AH, Kelley RK, Onodera C et al (2019) Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol 248:164–178. https://doi.org/10.1002/path.5243CrossRefPubMed

Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M et al (2018) Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res 24:4154–4161. https://doi.org/10.1158/1078-0432.CCR-18-0078CrossRefPubMedPubMedCentral

Kendre G, Murugesan K, Brummer T, Segatto O, Saborowski A, Vogel A (2023) Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J Hepatol 78:614–626. https://doi.org/10.1016/j.jhep.2022.11.030CrossRefPubMed

10.

Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H et al (2014) Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59:1427–1434. https://doi.org/10.1002/hep.26890CrossRefPubMed

11.

Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K et al (2015) Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun 6:6087. https://doi.org/10.1038/ncomms7087CrossRefPubMed

12.

Silverman IM, Hollebecque A, Friboulet L, Owens S, Newton RC, Zhen H et al (2021) Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov 11:326–339. https://doi.org/10.1158/2159-8290.CD-20-0766CrossRefPubMed

13.

Katoh M (2019) Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol 16:105–122. https://doi.org/10.1038/s41571-018-0115-yCrossRefPubMed

14.

Neumann O, Lehmann U, Bartels S, Pfarr N, Albrecht T, Ilm K et al (2023) First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma. J Pathol Clin Res 9:100–107. https://doi.org/10.1002/cjp2.308CrossRefPubMedPubMedCentral

15.

Jeon Y, Kwon SM, Rhee H, Yoo JE, Chung T, Woo HG et al (2023) Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma. Hepatology 77:92–108. https://doi.org/10.1002/hep.32397CrossRefPubMed

16.

Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB et al (2023) Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 388:228–239. https://doi.org/10.1056/NEJMoa2206834CrossRefPubMed

17.

Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C et al (2022) Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature 608:609–617. https://doi.org/10.1038/s41586-022-05066-5CrossRefPubMedPubMedCentral

18.

Uson Junior PLS, DeLeon TT, Bogenberger JM, Pai RK, Kosiorek HE, Yin J et al (2021) FGFR2-IIIb expression by immunohistochemistry has high specificity in cholangiocarcinoma with FGFR2 genomic alterations. Dig Dis Sci https://doi.org/10.1007/s10620-021-07303-9

19.

Toshida K, Itoh S, Yugawa K, Kosai Y, Tomino T, Yoshiya S et al (2023) Prognostic significance for recurrence of fibroblast growth factor receptor 2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection. Hepatol Res 53:432–439. https://doi.org/10.1111/hepr.13875CrossRefPubMed

20.

Liu PCC, Koblish H, Wu L, Bowman K, Diamond S, DiMatteo D et al (2020) INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS One 15:e0231877. https://doi.org/10.1371/journal.pone.0231877CrossRefPubMedPubMedCentral

21.

Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21:671–684. https://doi.org/10.1016/S1470-2045(20)30109-1CrossRefPubMedPubMedCentral

22.

Sasaki M, Sato Y, Nakanuma Y (2022) Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma? Histopathology 80:859–868. https://doi.org/10.1111/his.14622CrossRefPubMed

23.

Tong Y, Zhao Z, Liu B, Bao A, Zheng H, Gu J et al (2018) 5′/3′ imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer. J Exp Clin Cancer Res 37:68. https://doi.org/10.1186/s13046-018-0735-1CrossRefPubMedPubMedCentral

24.

Theise ND, Nakashima O, Park YN, Nakanuma Y (2010) Combined hepatocellular-cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumours of the digenstive system, 4th edn. International Agency for Research on Cancer (IARC), Lyon, pp 225–227

25.

Sasaki M, Sato Y, Nakanuma Y (2019) Cholangiolocellular carcinoma with “ductal plate malformation” pattern may be characterized by ARID1A genetic alterations. Am J Surg Pathol 43:352–360. https://doi.org/10.1097/PAS.0000000000001201CrossRefPubMed

26.

Sasaki M, Sato Y, Nakanuma Y (2017) Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance. Histopathology 70:423–434. https://doi.org/10.1111/his.13084CrossRefPubMed

27.

Sasaki M, Sato Y, Nakanuma Y (2023) Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components. Histopathology 83:298–309. https://doi.org/10.1111/his.14932CrossRefPubMed

28.

Kobel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F et al (2016) Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res 2:247–258. https://doi.org/10.1002/cjp2.53CrossRefPubMedPubMedCentral

29.

Singh N, Piskorz AM, Bosse T, Jimenez-Linan M, Rous B, Brenton JD et al (2020) p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J Pathol 250:336–345. https://doi.org/10.1002/path.5375CrossRefPubMed

30.

Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T et al (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363:1532–1543. https://doi.org/10.1056/NEJMoa1008433CrossRefPubMedPubMedCentral

31.

Luchini C, Robertson SA, Hong SM, Felsenstein M, Anders RA, Pea A et al (2017) PBRM1 loss is a late event during the development of cholangiocarcinoma. Histopathology 71:375–382. https://doi.org/10.1111/his.13234CrossRefPubMedPubMedCentral

32.

Griewank KG, Muller H, Jackett LA, Emberger M, Moller I, van de Nes JA et al (2017) SF3B1 and BAP1 mutations in blue nevus-like melanoma. Mod Pathol 30:928–939. https://doi.org/10.1038/modpathol.2017.23CrossRefPubMedPubMedCentral

33.

Chapel DB, Schulte JJ, Berg K, Churg A, Dacic S, Fitzpatrick C et al (2020) MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Mod Pathol 33:245–254. https://doi.org/10.1038/s41379-019-0310-0CrossRefPubMed

34.

Calderaro J, Di Tommaso L, Maille P, Beaufrere A, Nguyen CT, Heij L et al (2022) Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. J Hepatol 77:1586–1597. https://doi.org/10.1016/j.jhep.2022.07.019CrossRefPubMed

35.

Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE et al (2014) p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 158:579–592. https://doi.org/10.1016/j.cell.2014.05.051CrossRefPubMedPubMedCentral

Title: Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study
Authors: Motoko Sasaki
Yasunori Sato
Yasuni Nakanuma
Publication date: 27-03-2024
Publisher: Springer Berlin Heidelberg
Keywords: Cholangiocarcinoma
Cholangiocarcinoma
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Virchows Archiv
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-024-03792-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study

Abstract

Graphical Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Graphical Abstract

Please log in to get access to this content